We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Staining Method Enables Nano-CT Imaging of Tissue

By LabMedica International staff writers
Posted on 07 Mar 2018
Tissue sectioning is a routine procedure in hospitals, for instance to investigate tumors. More...
As the name implies, it entails cutting samples of body tissue into thin slices, then staining them and examining them under a microscope.

The most obvious way forward for three-dimensional examination of the tissues lies in computed tomography (CT) scanning, also a standard method used in everyday clinical workflows. Soft tissue is notoriously difficult to examine using CT equipment. Samples have to be stained to render them visible in the first place. Stains for CT scanning are sometimes highly toxic, and they are also extremely time-consuming to apply.

Scientists at the Technical University of Munich (Garching, Germany) have developed a cytoplasm-specific staining method tailored for X-ray CT that enables a routine and efficient 3D volume screening at high resolutions. The technique is fully compatible with conventional histology and allows further histological investigations, as demonstrated for a mouse kidney. The team described an eosin-based preparation overcoming the challenges of contrast enhancement and selectivity for certain tissues. The eosin-based staining protocol is suitable for whole-organ staining, which then enables high-resolution microCT imaging of whole organs and nanoCT imaging of smaller tissue pieces retrieved from the original sample. The nano-CT system delivers resolutions of up to 100 nm and is suitable for use in typical laboratory settings.

The results of the study demonstrate suitability of the eosin-based staining method for diagnostic screening of 3D tissue samples without impeding further diagnostics through histological methods. Madleen Busse, PhD, a chemist and lead author of the study, said, “Our approach included developing a special pre-treatment so that we can use eosin anyway. The staining method is so time-efficient that it is also suited to everyday clinical workflows. Another important benefit is that there are no problems using established methods to examine the tissue sample following the scan.” The study was published on February 20, 2018, in the journal Proceedings of the National Academy of Sciences (PNAS).


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
HPV Molecular Test
BD Onclarity HPV Assay
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.